Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:03:04.829Z.
Calculation as of: 2026-10-06T17:03:04.829Z.
Quote observation: 2026-10-06T17:00:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$991.20M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$983.38M
EBITDA Yield
8.71%
TTM Avg
9.22%
3Y Avg
7.66%
5Y Avg
6.32%
Market Cap
$1.02B
EBITDA Yield
3.57%
TTM Avg
3.47%
3Y Avg
3.47%
5Y Avg
3.47%
Market Cap
$979.81M
EBITDA Yield
20.70%
TTM Avg
16.68%
3Y Avg
16.68%
5Y Avg
16.68%
Market Cap
$979.53M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
EBITDA Yield
N/A
TTM Avg
3.55%
3Y Avg
3.10%
5Y Avg
3.10%
Market Cap
$1.04B
EBITDA Yield
N/A
TTM Avg
50.22%
3Y Avg
50.22%
5Y Avg
50.22%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.20M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $983.38M | 8.71% | 9.22% | 7.66% | 6.32% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 3.57% | 3.47% | 3.47% | 3.47% |
| MeiraGTx Holdings plc (MGTX)vs › | $979.81M | 20.70% | 16.68% | 16.68% | 16.68% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $979.53M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | N/A | 3.55% | 3.10% | 3.10% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | N/A | 50.22% | 50.22% | 50.22% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.03B | N/A | 5.69% | 5.69% | 5.69% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
